Literature DB >> 18992364

Drug discovery: new models for industry-academic partnerships.

Cathy J Tralau-Stewart1, Colin A Wyatt, Dominique E Kleyn, Alex Ayad.   

Abstract

The re-focusing of pharmaceutical industry research away from early discovery activities is stimulating the development of novel models of drug discovery, notably involving academia as a 'front end'. In this article the authors explore the drivers of change, the role of new entrants (universities with specialised core facilities) and novel partnership models. If they are to be sustainable and deliver, these new models must be flexible and properly funded by industry or public funding, rewarding all partners for contributions. The introduction of an industry-like process and experienced management teams signals a revolution in discovery that benefits society by improving the value gained from publicly funded research.

Mesh:

Year:  2008        PMID: 18992364     DOI: 10.1016/j.drudis.2008.10.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  30 in total

1.  Drug Discovery in Academia- the third way?

Authors:  Julie Frearson; Paul Wyatt
Journal:  Expert Opin Drug Discov       Date:  2010-10-01       Impact factor: 6.098

2.  Measuring the value of public-private partnerships in the pharmaceutical sciences.

Authors:  Tom R Denee; Arnold Sneekes; Pieter Stolk; Antoine Juliens; Jan A M Raaijmakers; Michel Goldman; Daan J A Crommelin; Jorg W Janssen
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

3.  Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative.

Authors:  Jeffrey L Cummings; John Ringman; Karen Metz
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Drug repurposing and beyond: the fundamental role of pharmacology.

Authors:  Diana Amantea; Michelangelo Certo; Giacinto Bagetta
Journal:  Funct Neurol       Date:  2015 Jan-Mar

5.  Preclinical research strategies for newly approved drugs as reflected in early publication patterns.

Authors:  Ursula Köster; Ingo Nolte; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-11-26       Impact factor: 3.000

6.  Academic-Industrial Collaboration: Toward the Consilience of Two Solitudes.

Authors:  Stephen Hanessian
Journal:  ACS Med Chem Lett       Date:  2015-12-22       Impact factor: 4.345

7.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

Review 8.  Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery.

Authors:  Michael R Barnes; Lee Harland; Steven M Foord; Matthew D Hall; Ian Dix; Scott Thomas; Bryn I Williams-Jones; Cory R Brouwer
Journal:  Nat Rev Drug Discov       Date:  2009-07-17       Impact factor: 84.694

9.  US academic drug discovery.

Authors:  Stephen Frye; Marina Crosby; Teresa Edwards; Rudolph Juliano
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 10.  HTS and hit finding in academia--from chemical genomics to drug discovery.

Authors:  Julie A Frearson; Iain T Collie
Journal:  Drug Discov Today       Date:  2009-09-28       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.